Boryung’s new antihypertensive agent gets NET certification

Published: 2011-07-01 06:56:00

Updated: 2011-07-01 06:56:00

Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, said recently that its novel antihypertensive drug “Kanarb (fimasartan)” has received the domestic New Excellent Technology (NET) certificate from the Ministry of Health and Welfare.

Kanarb, one of angiotensin II rece...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK